Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
631.81
-1.09 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
715,198
Open
635.99
Bid (Size)
631.86 (40)
Ask (Size)
640.22 (40)
Prev. Close
632.90
Today's Range
626.86 - 638.30
52wk Range
518.90 - 821.11
Shares Outstanding
91,779,465
Dividend Yield
0.60%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side
↗
Today 5:45 EDT
Via
Chartmill
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could
↗
Today 5:04 EDT
These stocks are better bets to skyrocket than the much-hyped rocket stock.
Via
The Motley Fool
Performance
YTD
-18.6%
-18.6%
1 Month
+2.8%
+2.8%
3 Month
-15.7%
-15.7%
6 Month
-19.1%
-19.1%
1 Year
+20.3%
+20.3%
More News
Read More
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
↗
June 27, 2026
Via
The Motley Fool
Topics
Initial Public Offering
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals
↗
June 12, 2026
Via
Chartmill
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
June 25, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Underrated Weight Loss Stocks to Buy and Hold
↗
June 23, 2026
Via
The Motley Fool
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
June 22, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
This Stock Is Up 58% This Year. Is It too Late to Buy?
↗
June 17, 2026
Via
The Motley Fool
3 Profitable Stocks We Think Twice About
June 17, 2026
Via
StockStory
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
June 10, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Top S&P500 movers in Monday's session
↗
June 08, 2026
Via
Chartmill
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
June 04, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Regeneron (REGN) Stock Is Trading Up Today
June 03, 2026
Via
StockStory
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
June 03, 2026
Via
StockStory
Topics
Stocks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
3 Nasdaq 100 Stocks We Find Risky
June 01, 2026
Via
StockStory
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
May 28, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
May 27, 2026
From
Grabar Law Office
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
↗
May 26, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
May 26, 2026
From
Grabar Law Office
Via
GlobeNewswire
Amylyx Stock: Why the Full Pipeline Story Matters
↗
May 24, 2026
Via
MarketBeat
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron
May 22, 2026
Via
StockStory
Topics
Artificial Intelligence
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
May 22, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 631.81
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 06/29/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 57.99B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 58B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.